NF-κB-IN-19

NF-κB-IN-19 (Compound 8) is an NF-κB inhibitor. NF-κB-IN-19 effectively induces DNA damage, promotes the generation of ROS, and induces autophagy and apoptosis through the NF-κB signaling pathway in tumor cells. In addition, NF-κB-IN-19 can inhibit the levels of VEGF and HIF-1α, and exert antiproliferative activity in tumor cells through the PI3K/AKT and STAT-3 pathways. NF-κB-IN-19 can effectively overcome cisplatin resistance and has anti-tumor activity[1].

Product Specifications

UNSPSC

12352005

Target

Akt; Apoptosis; Autophagy; HIF/HIF Prolyl-Hydroxylase; NF-κB; PI3K; Reactive Oxygen Species (ROS) ; STAT

Related Pathways

Apoptosis; Autophagy; Immunology/Inflammation; JAK/STAT Signaling; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt

Field of Research

Cancer; Inflammation/Immunology

Smiles

O=C(CCCC(O[Pt]([NH3])(Cl)(Cl)([NH3])Cl)=O)N1C/C(C(/C(C1)=C/C2=C(C=CC=C2)F)=O)=C\C3=CC=CC=C3F

Molecular Formula

C24H26Cl3F2N3O4Pt

Molecular Weight

759.92

References & Citations

[1]Wang M, et al. Discovery of a Novel EF24 Analogue-Conjugated Pt (IV) Complex as Multi-Target Pt (IV) Prodrugs Aims to Enhance Anticancer Activity and Overcome Cisplatin Resistance. J Med Chem. 2025 Mar 13;68 (5) :5597-5615.